| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424647000 | Ferric | 21 |
| 20080274210 | Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Method of Making Same - The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 11-06-2008 |
| 20090041858 | Haemostatic Compositions Thickened by Polymers Containing Nitrogen Moieties - The present invention is the development of haemostatic compositions that use nitrogen containing organic polymers in combination with haemostatic agents to create a gel form. Compositions utilizing the polymers exhibit relatively lower concentrations of haemostatic agents, drawing benefits from such lower concentrations as they limit unwanted side effects of the haemostatic agents. Preferred compositions utilize Poly(N-vinylpyrrolidone), Poly(2-ethyl-2-oxazoline) as thickening agents and ferric sulfate as an active ingredient. | 02-12-2009 |
| 20090110752 | COMPOSITION FOR CONTROLLING BLOOD GLUCOSE AND METHOD THEREOF - A composition for controlling a blood glucose and a method thereof are provided. The composition comprises a far-infrared ray releasing substance, wherein the composition reduces the blood glucose of a subject via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of providing a far-infrared ray releasing substance having an oxide mineral as a main component, and disposing the far-infrared ray releasing substance in a place close to a subject in an appropriate distance, wherein the subject has an insulin resistance and the appropriate distance is within an irradiation range of the far infrared ray. | 04-30-2009 |
| 20090297628 | Use of iron in the form of a stone extract as stimulus of the synthesis of collagen by skin fibroblasts - Use of a stone extract as stimulant of the synthesis of collagen by skin fibroblasts. | 12-03-2009 |
| 20100136135 | Method of Selecting Phosphate Binder and its Uses Thereof - A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells. | 06-03-2010 |
| 20110014301 | METAL COMPOUNDS, MIXED OR SULPHATED, AS PHOSPHATE BINDERS - A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8. | 01-20-2011 |
| 20110081425 | PESTICIDAL COMPOSITIONS AND METHODS - The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material. | 04-07-2011 |
| 20110142960 | NUTRITIONAL SUPPLEMENT FOR OSTEOARTHRITIS - The present invention relates to a method of treating osteoarthritis by administering a mineral composition in the form of a nutritional supplement, where the mineral composition may contain Smectite, Gypsum, Quartz, Feldspar, Jarosite, Kaolinite and/or Zeolite. | 06-16-2011 |
| 20120034316 | PHARMACEUTICAL COMPOSITIONS FOR DEHYDRATING, ATROPHYING AND ELIMINATING PATHOLOGICAL TISSUES - The present invention provides a pharmaceutical composition for dehydrating, atrophying and eliminating pathological tissues comprising inorganic polymeric ferric salt and/or inorganic polymeric ferric salt composite as its active ingredients, in which the inorganic polymeric ferric salt is polyferric sulfate, and the inorganic polymeric ferric salt composite is selected from a group consisting of poly-silicate ferric salts, polyphosphate ferric salts and their analogue. A surprising medical effect can be reached by treating pathological tissues with the pharmaceutical composition of the present invention which will make the treated pathological tissues dehydrated, atrophied, and absorbed or sloughed off. The pharmaceutical composition of the present invention is cost-effective, convenient to use and has significant effects in treatment of hemorrhoids, hemangiomas, varix, hygromas, abscess, tumors, scalding and burning wounds, bleeding traumatic wounds, and/or local injuries caused by chemical agents or microorganism. | 02-09-2012 |
| 20120093943 | PHARMACEUTICALLY ACTIVE COMPOUNDS, THEIR MANUFACTURE, COMPOSITIONS CONTAINING THEM, AND THEIR USE - A substance for use as a medicament, comprises a solid mixed metal compound of formula (I): M | 04-19-2012 |
| 20120100226 | PREVENTIVE REMEDIAL THERAPEUTIC AGENT FOR PHOSPHORUS IMPAIRMENT, ORAL AGENT FOR ADSORBING PHOSPHATE ION CONTAINED IN FOOD, BEVERAGE AND CHEMICAL, AND PROCESS FOR PRODUCING THEM - The present invention provides agents for preventing, improving or treating phosphorus-related disorders and oral preparations; agents high in biosafety and phosphorus adsorptive power, which contain, as an active ingredient, ferric hydroxide as produced under such conditions that a ferrous species is present. | 04-26-2012 |
| 20120141602 | SYSTEMS CONTAINING MAGNETIC NANOPARTICLES AND POLYMERS, SUCH AS NANOCOMPOSITES AND FERROFLUIDS, AND APPLICATIONS THEREOF - The present invention relates to a system comprising magnetic nanoparticles of a metal oxide and a polymer, which in turn contains monomers with different functional groups. This system can be solid (nanocomposite) or liquid (ferrofluid). The present invention also relates to a process for obtaining the system, as well as its use, mainly in biotechnological, veterinary and medical applications, such as, for example, for the diagnosis and treatment of human diseases. | 06-07-2012 |
| 20130189375 | BIOCIDAL IRON OXIDE COATING, METHODS OF MAKING, AND METHODS OF USE - Embodiments of the present disclosure include visible light antimicrobial materials comprising α-Fe | 07-25-2013 |
| 20130316018 | Manufacture process for the preparation of an iron containing phosphate adsorbent - The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties. | 11-28-2013 |
| 20140335202 | Iron Sulfate-Based Phosphate Adsorbent - The present invention relates to a process for the preparation of a novel composition, and to the use of the composition as a phosphate adsorbent, in particular for administration in humans or animals. | 11-13-2014 |
| 20150132406 | METHOD OF SELECTING PHOSPHATE BINDER AND ITS USES THEREOF - A method of selecting or determining a candidate compound suitable for use as a phosphate binder is disclosed. The candidate compound includes ferric compounds, ferric compound complexes, and their derivatives, salts, analogs, and metabolites. The effectiveness of the candidate compound as a phosphate binder is evaluated by a method, comprising measuring and correlating reduction of phosphate concentration in solution and reduction of phosphate absorption in cells. | 05-14-2015 |
| 20150132407 | Water-Insoluble, Iron-Containing Mixed Metal, Granular Material - There is provided a granular material comprising (i) at least 50% by weight based on the weight of the granular material of solid water-insoluble mixed metal compound capable of binding phosphate of formula (I): M | 05-14-2015 |
| 20150313939 | ORAL IRON (III) BASED PHOSPHATE ADSORBENT FOR TREATING IRON-DEFICIENCY ANEMIA IN CATS WITH CHRONIC KIDNEY DISEASE - The invention relates to the new use of an oral iron(III)-based phosphate adsorbent, for example SBR759, in the treatment of iron deficiency anaemia in cats with chronic kidney disease. | 11-05-2015 |
| 20150313940 | TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S) - The present invention is relative to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB. | 11-05-2015 |
| 20160030394 | Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 02-04-2016 |
| 20160375057 | THERAPEUTIC COMPOSITIONS AND METHODS INVOLVING CELL-PERMEABLE IRON - This disclosure describes, in one aspect, therapeutic methods that involve administering cell-permeable iron to a subject. In some cases, the cell-permeable iron may be co-administered to the subject with a chemotherapeutic agent or radiation treatment, each in an amount that, in combination with the other, is effective to ameliorate at least one symptom or clinical sign of the tumor. In other cases, the cell-permeable iron may be administered in an amount effective to inhibit angiogenesis. | 12-29-2016 |
